Quantcast

Latest Targeted therapy Stories

2014-02-18 23:30:30

Company Will Present its Targeted and Personalized Medicine Approach to Lung Cancer Somerville, MA (PRWEB) February 18, 2014 Andarix Pharmaceuticals, a clinical stage company, announces that it has been selected to present its targeted lung cancer therapy at the 14th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting, also known as the Santa Monica Lung Cancer Meeting. This annual invitation-only meeting gathers the top scientists and clinicians to discuss the latest...

2014-02-14 23:02:22

New research report “Breast Cancer: New targeted therapies transform treatment - KOL Insight” worked out by FirstWord is now available at MarketPublishers.com. London, UK (PRWEB) February 14, 2014 Currently, hormone, immuno-, chemo- and target therapies are the four main types of cancer therapy, with target therapy sector accounting for the dominant share of the overall cancer therapy market. In spite of the continuous improvements in the cancer diagnosis together with the development...

2014-02-13 04:20:48

Pierre Fabre are thus reinforcing their oncology portfolio which already enjoys a combination of chemotherapies, monoclonal antibodies and immuno-conjugates assets at various development phases CASTRES, France and BANGALORE, India, February 13, 2014 /PRNewswire/ -- Pierre Fabre, the third largest French pharmaceutical company, and Aurigene, a leading biotech company based in India, today announced that the two companies have entered into a collaborative license, development and...

2014-02-12 23:25:02

ION Solutions, a diversified physician services organization whose membership represents more than half of the private practice oncologists in the United States, today announced the selection of Foundation Medicine as its preferred partner for comprehensive cancer genomic profiling services. Frisco, Texas (PRWEB) February 12, 2014 ION Solutions, a diversified physician services organization whose membership represents more than half of the private practice oncologists in the United...

2014-02-03 23:02:17

Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912. Philadelphia, PA (PRWEB) February 03, 2014 The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) announced today that it has activated E1912, a randomized phase III clinical trial to evaluate the ability of the combination of ibrutinib and rituximab to prolong progression-free survival in previously...

2014-01-29 16:28:12

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5s2nhx/drug_delivery_in) has announced the addition a new report "Drug Delivery in Cancer - Technologies, Markets and Companies" [http://www.researchandmarkets.com/research/5s2nhx/drug_delivery_in ] to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Drug delivery remains a challenge in management of cancer. Approximately 12.5...

2014-01-22 23:25:28

PhenoPath is one of the first labs in the US to adopt all the complex changes of the 2013 ASCO-CAP HER2 Testing Guideline updates in breast cancer. Seattle, WA (PRWEB) January 22, 2014 PhenoPath is one of the first labs in the US to adopt all the complex changes of the 2013 American Society of Clinical Oncology and College of American Pathologists (ASCO-CAP) HER2 Testing Guideline updates in breast cancer. PhenoPath offers both IHC and FISH—including options for alternative Chromosome...

2014-01-17 08:22:52

Molecularly-Guided Therapies of Critical Importance for Rare Cancers with Fewer Treatment Options IRVING, Texas, Jan. 17, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present tumor profiling studies on neuroendocrine and appendiceal cancers at the 2014 Gastrointestinal Cancers Symposium held this week in San Francisco, Calif. These studies provide key clinical insights on potential treatment...

2014-01-16 16:24:37

Research uncovers clinically actionable biomarker targets and key treatment insights for colorectal, gastric, neuroendocrine and appendiceal cancer patients IRVING, Texas, Jan. 16, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present multiple tumor profiling studies at the 2014 Gastrointestinal Cancers Symposium held this week in San Francisco, Calif. This research demonstrates the impact of Caris...

2014-01-16 16:23:55

Five Distinguished Researchers Receive First-Time Grant WHITE PLAINS, N.Y., Jan. 16, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today is pleased to announce the researchers who will receive funding through The Screen to Lead program - a new grant program to support drug discovery specifically directed toward medicinal chemistry and/or drug target screening in blood cancers. LLS recognizes investigators' significant need for resources to develop small molecules...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related